|
|
Volumn 301, Issue 8, 2009, Pages 813-815
|
|
Amid lingering questions, FDA reprieves LDL cholesterol-lowering medication
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
EZETIMIBE;
EZETIMIBE PLUS SIMVASTATIN;
HYPOCHOLESTEROLEMIC AGENT;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
PLACEBO;
SIMVASTATIN;
AZETIDINE DERIVATIVE;
BIOLOGICAL MARKER;
EZETIMIBE SIMVASTATIN COMBINATION;
EZETIMIBE-SIMVASTATIN COMBINATION;
AORTA STENOSIS;
ARTERY INTIMA PROLIFERATION;
ATHEROSCLEROSIS;
CANCER RISK;
CARDIOVASCULAR RISK;
CLINICAL TRIAL;
DISEASE COURSE;
ECHOGRAPHY;
FAMILIAL HYPERCHOLESTEROLEMIA;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
HYPERCHOLESTEROLEMIA;
NEOPLASM;
PRIORITY JOURNAL;
SHORT SURVEY;
BLOOD;
DRUG APPROVAL;
DRUG COMBINATION;
NOTE;
RANDOMIZED CONTROLLED TRIAL;
UNITED STATES;
ANTICHOLESTEREMIC AGENTS;
AZETIDINES;
BIOLOGICAL MARKERS;
CHOLESTEROL, LDL;
DRUG APPROVAL;
DRUG COMBINATIONS;
HUMANS;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
SIMVASTATIN;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 61449221074
PISSN: 00987484
EISSN: 15383598
Source Type: Journal
DOI: 10.1001/jama.2009.196 Document Type: Short Survey |
|
Times cited : (3)
|
|
References (0)
|